[May 4, 2023] – [Pamplona, Navarra] – The Foundation for Prader Willi Research (FPWR) has provided a new venture philanthropy award, in the form of a convertible loan, to Palobiofarma S.L.,...
Palobiofarma has received the approval of the European project that finances Phase II of the PBF-680 product in COPD. Additionally, it offers the possibility of partial financing of Phase III of...
The Phase II trial studied the safety, tolerability, and preliminary efficacy of PBF-677 in patients with mild to moderate Ulcerative Colitis in flair condition on top of the standard of care...
The Phase II trial studies the safety, tolerability and preliminary efficacy of PBF-677 in patients with mild to moderate Ulcerative Colitis in flair condition on top of the standard of care...
The results of an allergen POC trial in asthmatics will summarized by Dr. David Ramos, principal investigator of the PBF-680 clinical program, in an oral presentation titled: PBF-680, an oral A1...
The results confirm a clinically and statistically significant improvement in trough FEV1 of asthmatic patients taking 10mg of PBF-680 for 14 days compared to placebo. Additionally, patients...
The company announced the initiation a of a drug discovery program towards the identification of novel oral drugs specifically designed to treat infections caused by Corona viruses. Recent...
Includes royalty interest in NIR178 September 30 2019 XOMA Corporation (NASDAQ: XOMA), announced today it has acquired a royalty interest in six clinical-stage assets targeting the adenosine...
Palobiofarma has started the clinical development of PBF-1650, a novel treatment of autoimmune diseases, like NASH and psoriasis. The “first in human” study will take place at the University...
Palobiofarma has completed the dose escalation of the Phase I clinical trial evaluating the safety and tolerability of the novel PDE10/A2a dual antagonist PBF-999 in patients with solid tumors....
